Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2009

View Archived Issues

Rosuvastatin reduces high sensitivity C-reactive protein and LDLC

Effects of bivalirudin in HORIZONS-AMI trial independent of clopidogrel dose

Novel MEK inhibitors identified by Curis

Abbott describes novel prodrugs of a histamine H3 receptor ligand

T-type calcium channel inhibitors claimed by Ewha Womans University as analgesics

Boehringer Ingelheim claims novel calcitonin gene-related peptide antagonists

Arete Therapeutics presents epoxide hydrolase inhibitors for the treatment of hypertension

First human pharmacokinetic data for anticancer agent KP-1019 reported

Merck & Co. and Santen enter licensing agreement for tafluprost

Pro-Pharmaceuticals' Davanat was not associated with mucositis in phase I and II trials

Pfizer and Medivation initiate phase III trial of Dimebon added to donepezil in AD patients

Novel corticotropin-releasing factor receptor antagonists developed as anxiolytics

Cannasat and IntelGenx report phase Ib results for buccal dronabinol

Etanercept to be studied in Kawasaki disease / News in Context

Infinity stops RING trial in advanced GIST, clinical trials to continue in other cancers

Novagali completes phase II Cyclokat trial in dry eye

Vyteris and Zealand Pharma sign collaboration agreement in transdermal peptide delivery

Tekmira files IND with FDA for phase I clinical trial of ApoB SNALP for LDL cholesterol

Asahi Kasei and Dong-A sign license agreement for BPH drug Flivas

XenoPort exercises co-promotion option contained in agreement with GSK for Solzira

Accera forms wholly owned subsidiary, Neuera Pharmaceuticals

Sirion reports interim phase II results for fenretinide

Ensemble forms alliance with Bristol-Myers Squibb to develop novel drug class

Cangene to supply the U.S. Department of Defense with VIG vaccine

Clinuvel provides update on afamelanotide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...